# Validation of the ELN2024 and Mayo genetic risk models in an external cohort of 352 patients with newly-diagnosed AML receiving less-intensive therapies

Code and data used for the validation of the 2024 European LeukemiaNet (ELN) and Mayo Clinic genetic risk models in patients with acute myeloid leukemia (AML) treated with low-dose cytarabine (LDAC) and Gemtuzumab ozogamicin monotherapy.

## Citation
M. Roncador, M. Marconato, J. W. Deuel, S. Balabanov
_Validation of the ELN2024 and Mayo genetic risk models in an external cohort of 352 patients with newly-diagnosed AML receiving less-intensive therapies_. Submitted.


## Licence
[GNU General Public License v3.0](https://choosealicense.com/licenses/gpl-3.0/)
